Product Description
Mechanisms of Action: COX Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Algeria | Australia | Bangladesh | Bulgaria | Canada | Chile | Egypt | Estonia | France | Hong Kong | Hungary | India | Ireland | Jordan | Lithuania | Malta | Mexico | Morocco | New Zealand | Norway | Pakistan | Peru | Philippines | Portugal | Russia | Saudi Arabia | Singapore | Spain | Sweden | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|